Mark Elliott Boulding - Aug 15, 2025 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Aug 15, 2025
Transactions value $
-$64,390
Form type
4
Date filed
8/19/2025, 04:30 PM
Previous filing
May 19, 2025
Next filing
Sep 15, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boulding Mark Elliott EXEC. VP AND CLO C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 2025-08-19 0001578852

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $72.3K +2.81K +2.71% $25.69 107K Aug 15, 2025 Direct F1
transaction PTCT Common Stock Sale -$137K -2.81K -2.64% $48.58 104K Aug 15, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -2.81K -10.15% $0.00 24.9K Aug 15, 2025 Common Stock 2.81K $25.69 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.24 to $49.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.